ARS Pharma (SPRY) Q4 2025 Earnings Transcript

ARS Pharmaceuticals reported full-year 2025 revenue of $84.3 million, including $72.2 million in U.S. net product revenue from its first full commercial year for neffy. Management said SG&A of $230.1 million will stay roughly flat in 2026 even as the sales force expands from 106 to 150 reps, funded by reallocating existing commercial spend. Prescriber adoption reached more than 22,500 HCPs, commercial coverage was 93%, and the company ended the year with $245 million in cash, supporting execution but with ongoing launch and reimbursement risks.

Analysis

The key second-order read is that SPRY is moving from a pure launch story to a workflow capture story. In this market, the winner is not simply the product with the best clinical profile, but the one that gets embedded into electronic renewal rails, prior-auth handling, and high-frequency office staff routines; that is why the sales-force redeploy and digital conversion funnel matter more than headline revenue growth. If management is right that refills only become meaningful later this year into 2027, the current period is the last window where share gains can compound before the installed base begins to self-fund repeat business.

The commercial mix also implies a near-term margin tension that is easy to miss: expanding field coverage while keeping SG&A flat sounds disciplined, but it likely shifts spend from lower-variance brand awareness into higher-variance conversion economics. That should improve ROI if access keeps widening, yet it also raises execution risk because the company is now betting that incremental call frequency at priority accounts converts faster than broad DTC saturation. In other words, 2026 is less about awareness acceleration and more about whether awareness can be converted into durable prescribing behavior before category incumbents adapt their own renewal defenses.

The biggest catalyst is payer normalization over the next 1-2 quarters. If unrestricted access broadens and prior-auth friction falls, the company gets a double benefit: higher conversion from new scripts and better gross-to-net predictability, which should support multiple expansion more than top-line growth alone. The main failure mode is that usage data and brand recall outpace replenishment, leaving the stock valued on a refills ramp that arrives too slowly versus consensus expectations.

Contrarian view: the market may be underestimating how sticky early prescriber concentration can be in a niche launch. If the top-decile allergists and pediatricians become repeat writers first, SPRY may not need broad primary-care penetration to sustain a strong growth curve; however, if those high-volume centers plateau, the stock will look like a one-product commercialization story with a long cash conversion runway but limited re-rating optionality.

Key Decisions for Investors

• Long SPRY into the next 1-2 quarters on access milestones, with a bias to add on evidence of unrestricted formulary wins; upside is multiple expansion if gross-to-net stabilizes near steady state, downside is a stalled refill curve.
• Buy SPRY call spreads 3-6 months out rather than outright equity if available, targeting a catalyst window around payer updates and back-to-school demand; this expresses upside to conversion inflection while limiting drawdown if adoption remains lumpy.
• Pair trade: long SPRY / short IQV on the thesis that increasing neffy penetration and electronic renewal workflows can create share gains in the epinephrine category while IQV is a cleaner proxy for launch/usage analytics but lacks direct product torque.
• If the stock rallies sharply before evidence of refill maturation, trim 25-35% and re-enter on any post-access pullback; the market is likely to overpay for awareness metrics before true renewal economics show up.
• For longer-horizon accounts, maintain a starter long in SPRY through 2027 only if Medicaid and unrestricted commercial coverage continue to widen; if coverage stalls, re-underwrite as a single-product launch with delayed cash flow inflection.